RESUMEN
OBJECTIVE: Topical fat reduction from the thigh in women using aminophylline cream has been demonstrated, but the local fat reduction in other body areas or in men by lowering the local lipolytic threshold has not been demonstrated. This study is designed to test the hypothesis that aminophylline cream application to the waist will reduce waist circumference compared with a control. RESEARCH METHODS AND PROCEDURES: Fifty men and women who are 21-65 years of age with a BMI greater than 27 kg/m(2) and a waist to hip ratio > or =average were randomized in a 1 : 1 ratio to 0.5% aminophylline cream to the waist twice a day or no treatment to the waist. All subjects were instructed to follow a 1200 kcal balanced diet, participate in a walking program and return biweekly to encourage compliance. A theophylline level was drawn monthly, and the waist, BMI and waist to hip ratio were remeasured at 12 weeks. RESULTS: At week 12, there was a significant reduction in BMI from baseline that was not different between the groups. The reduction in waist circumference was 11 +/- 1.0 cm in the aminophylline cream group and 5.0 +/- 0.6 cm in the control group (p < 0.001). The reduction in waist circumference was significant for both women and men, but the women lost significantly more waist girth. The waist to hip ratio, a measure of fat distribution, declined. Aminophylline levels were undetectable, and there were no adverse events. DISCUSSION: Aminophylline cream offers a safe and effective method for cosmetic local fat reduction from the waist.
Asunto(s)
Tejido Adiposo/efectos de los fármacos , Aminofilina/administración & dosificación , Obesidad/tratamiento farmacológico , Relación Cintura-Cadera , Administración Tópica , Adulto , Anciano , Índice de Masa Corporal , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores Sexuales , Pérdida de Peso/efectos de los fármacosRESUMEN
OBJECTIVE: Develop a dose-response curve for the effect of intranasal lidocaine on food intake. DESIGN: Healthy obese subjects had food intake, ratings of hunger, desire to eat, craving and fullness measured at lunch after an overnight fast. Four treatments were given as nose drops (0.5-0.6 ml per nostril) 5 min before the meal in a double-blind manner with a four period crossover design including a 7-day washout between periods. The treatments were saline, 2.5, 10 and 25 mg lidocaine per nostril. The order of administration was randomly assigned to each subject. Electrocardiograms, vital signs, chemistry panels, complete blood counts (CBC) and nasal inspections were carried out before and after each dose. SUBJECTS: Forty-seven subjects were screened, 34 were randomized and 20 subjects completed all four study periods in the trial. The subjects were 39+/-12.5 (s.d) years of age, had a weight of 91+/-13.0 kg, a height of 167+/-10.3 cm, 56% were women, 47% were African-American and 53% were Caucasian. MEASUREMENTS: Food intake, rating of hunger, desire to eat, craving and fullness are measures of efficacy. Adverse events, electrocardiograms, vital signs, chemistry panels, nasal inspections, CBC and physical exams are measures of safety. RESULTS: The mean reduction in food intake vs saline control in the 20 subjects completing all four study periods was 3.3+/-7% (s.d), 4.2+/-8.5% and 7.4+/-7.3% in the 2.5 mg, 10 and 25 mg per nostril groups, respectively (P=NS). Hunger and desire to eat in subjects who completed at least one study period decreased dose dependently (P<0.03, at the 25 mg per nostril dose). There were no clinically significant changes in safety measures, electrocardiograms, vital signs, chemistry panels, CBC or nasal inspections. CONCLUSION: Intranasal lidocaine reduced hunger and the desire to eat, but this did not translate into a significant reduction in food intake suggesting that intranasal lidocaine will not have value in treating obesity.